McClellan on PAT
This article was originally published in The Tan Sheet
Executive Summary
FDA will publish draft guidance on process analytical technology in September, Commissioner Mark McClellan, MD/PhD, tells Product Quality Research Institute workshop participants on Aug. 5. "I hope you will all have a chance in September...to read our new guidance document that we will be releasing on the use of process analytical technology in making possible innovations in drug manufacturing and quality assurance," he says. The draft guidance is expected to draw from the agency's existing guidance on 21 CFR Part 11 electronic record/electronic signatures (1"The Tan Sheet" Oct. 28, 2002, p. 12)...
You may also be interested in...
PAT Guidance Will Draw From Existing Electronic Records Guidances
FDA plans to draw from existing guidances to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.